Spotlight
Clinical
CME
Partners
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Azelastine eye drops receive FDA approval
Solna, Sweden-Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.
Solna, Sweden-Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.
The substance azelastine is an antihistamine and the eye drop formulation is approved for treatment of allergic conjunctivitis in adults and children. Meda is conducting a broad development program for the substance, both as eye drops and nasal spray. The azelastine eye drops sample is one part of that development.
Related Videos
Related Content
